Praxis Precision Medicines
NASDAQ · PRAX·Boston, MA·Small-cap·Phase 3
Clinical-stage biopharma developing therapies for CNS disorders including epilepsy, essential tremor, and major depressive disorder. Lead asset ulixacaltamide is a T-type calcium channel blocker with positive Phase 3 data and FDA-accepted NDA for essential tremor.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Praxis February 2026 Corporate Presentation | Corporate overview | February 19, 2026 | 57 |